These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 21491667)
41. Peripheral T-cell lymphoma: a case-based discussion of recent advances in patient management. Franco CM; Popplewell LL; Horwitz SM Clin Adv Hematol Oncol; 2011 Apr; 9(4 Suppl 9):1-16. PubMed ID: 21559001 [TBL] [Abstract][Full Text] [Related]
42. Malignant lymphomas in the elderly. O'Reilly SE; Connors JM; Macpherson N; Klasa R; Hoskins P Clin Geriatr Med; 1997 May; 13(2):251-63. PubMed ID: 9115450 [TBL] [Abstract][Full Text] [Related]
43. Difference in prognosis between T- and B-cell lymphomas: clinical study at Shikoku Cancer Center Hospital. Toki H; Okabe K; Kimura Y; Yumoto Y; Morita M; Ogushi I; Koike S; Takashima S; Sato G; Moriwaki S Jpn J Clin Oncol; 1986 Mar; 16(1):41-8. PubMed ID: 3486301 [TBL] [Abstract][Full Text] [Related]
44. Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma. Wilder RB; Rodriguez MA; Ha CS; Pro B; Hess MA; Cabanillas F; Cox JD Cancer; 2001 Jun; 91(12):2440-6. PubMed ID: 11413536 [TBL] [Abstract][Full Text] [Related]
45. Low grade malignant non-Hodgkin's lymphomas and peripheral pleomorphic T-cell lymphomas in childhood--a BFM study group report. Bucsky P; Feller AC; Reiter A; Beck J; Bertram U; Eschenbach C; Gerein V; Lakomek M; Stollmann B; Tausch W Klin Padiatr; 1990; 202(4):258-61. PubMed ID: 2203939 [TBL] [Abstract][Full Text] [Related]
46. Hematopoietic stem cell transplantation in the treatment of peripheral T-cell lymphomas. Majhail NS; Burns LJ Curr Hematol Rep; 2005 Jul; 4(4):252-9. PubMed ID: 16009039 [TBL] [Abstract][Full Text] [Related]
47. The aggressive peripheral T-cell lymphomas: 2012 update on diagnosis, risk stratification, and management. Armitage JO Am J Hematol; 2012 May; 87(5):511-9. PubMed ID: 22508369 [TBL] [Abstract][Full Text] [Related]
48. Molecular predictors of response in aggressive T-cell lymphomas. Foss FM Cancer J; 2011; 17(2):142-8. PubMed ID: 21427558 [TBL] [Abstract][Full Text] [Related]
49. Changing the paradigms of treatment in peripheral T-cell lymphoma: from biology to clinical practice. O'Connor OA; Bhagat G; Ganapathi K; Pedersen MB; D'Amore F; Radeski D; Bates SE Clin Cancer Res; 2014 Oct; 20(20):5240-54. PubMed ID: 25320373 [TBL] [Abstract][Full Text] [Related]
57. Genomic signatures in T-cell lymphoma: How can these improve precision in diagnosis and inform prognosis? Iqbal J; Wilcox R; Naushad H; Rohr J; Heavican TB; Wang C; Bouska A; Fu K; Chan WC; Vose JM Blood Rev; 2016 Mar; 30(2):89-100. PubMed ID: 26319391 [TBL] [Abstract][Full Text] [Related]
58. New drugs for aggressive B-cell and T-cell lymphomas. Murawski N; Pfreundschuh M Lancet Oncol; 2010 Nov; 11(11):1074-85. PubMed ID: 21051020 [TBL] [Abstract][Full Text] [Related]
59. Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma. Foss FM Expert Opin Drug Metab Toxicol; 2011 Sep; 7(9):1141-52. PubMed ID: 21726160 [TBL] [Abstract][Full Text] [Related]
60. Novel targeted therapies in peripheral T cell lymphoma. Jagadeesh D; Smith MR Discov Med; 2013 Jun; 15(85):367-78. PubMed ID: 23819951 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]